Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Respiratory Tract Neoplasms 2Colorectal Neoplasms 2Thyroid Carcinoma, Anaplastic 1Neoplasm Metastasis 1Advanced Non-small Cell Lung Cancer (NSCLC) 1Advanced Cancer 1

Interventions

Carboplatin 369Pemetrexed 310pembrolizumab 303Cisplatin 244Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28tislelizumab 26cemiplimab 26avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × efatutazone × Clear all
NCT01199068 2021-05-13

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
15 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT01199055 2020-07-07

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
16 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT00806286 2020-05-13

Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Completed
111 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡